NDAINTRAVENOUSSOLUTION
Approved
Feb 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PREVDUO is a fixed-dose combination of neostigmine methylsulfate (an acetylcholinesterase inhibitor) and glycopyrrolate (an anticholinergic agent) administered intravenously. It is indicated for reversal of neuromuscular blockade in patients who have received neuromuscular blocking agents during anesthesia. The combination works by inhibiting acetylcholinesterase to increase acetylcholine levels while glycopyrrolate blocks muscarinic side effects of neostigmine.
Peak12.3 years to LOE
Recent approval (Feb 2023) positions this product in growth-to-peak phase with opportunities for field team expansion and formulary management across perioperative settings.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PREVDUO represents an emerging asset in the perioperative anesthesia market with limited current job openings but growing commercial potential post-approval. Career growth will depend on adoption velocity in operating rooms and formulary penetration, creating opportunities in field-based and account management roles over 2-3 years.
Brand ManagerField Sales Representative
Worked on PREVDUO at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.